Afatinib versus cisplatin plus pemetrexed in Japanese patients with advanced non-small cell lung cancer harboring activatingEGFRmutations: Subgroup analysis of LUX-Lung 3-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Afatinib versus cisplatin plus pemetrexed in Japanese patients with advanced non-small cell lung cancer harboring activatingEGFRmutations: Subgroup analysis of LUX-Lung 3

Published:2015-07-25 Issue:9 Volume:106 Page:1202-1211
ISSN:1347-9032
Container-title:Cancer Science
language:en
Short-container-title:Cancer Sci

Author:

Kato Terufumi¹,Yoshioka Hiroshige²,Okamoto Isamu³,Yokoyama Akira⁴,Hida Toyoaki⁵,Seto Takashi⁶,Kiura Katsuyuki⁷,Massey Dan⁸,Seki Yoko⁹,Yamamoto Nobuyuki¹⁰

Affiliation:

1. Kanagawa Cardiovascular and Respiratory Center; Yokohama Japan

2. Kurashiki Central Hospital; Kurashiki Japan

3. Kyusyu University Hospital; Fukuoka Japan

4. Niigata Cancer Center Hospital; Niigata Japan

5. Aichi Cancer Center Hospital; Nagoya Japan

6. National Kyushu Cancer Center; Fukuoka Japan

7. Okayama University Hospital; Okayama Japan

8. Boehringer Ingelheim; Bracknell UK

9. Nippon Boehringer Ingelheim; Tokyo Japan

10. Wakayama Medical University; Wakayama Japan

Funder

Boehringer Ingelheim

Nippon Boehringer Ingelheim

Pfizer

Chugai Pharmaceutical Co.

AstraZeneca

Takeda Pharmaceuticals U.S.A.

Taiho Pharmaceutical

Kirin-Kyoma

Shionogi

Bristol-Myers Squibb

Eli Lilly

Publisher

Wiley

Subject

Cancer Research,Oncology,General Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/cas.12723/fullpdf

Reference33 articles.

1. Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence;Mitsudomi;J Clin Oncol,2005

2. Mutation in the tyrosine kinase domain of epidermal growth factor receptor is a predictive and prognostic factor for gefitinib treatment in patients with non-small cell lung cancer;Chou;Clin Cancer Res,2005

3. The transcriptional landscape and mutational profile of lung adenocarcinoma;Seo;Genome Res,2012

4. Mutations in the tyrosine kinase domain of the epidermal growth factor receptor in non-small cell lung cancer;Yang;Clin Cancer Res,2005

5. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma;Mok;N Engl J Med,2009

Cited by 98 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Strong PD-L1 affect clinical outcomes in advanced NSCLC treated with third-generation EGFR-TKIs;Future Oncology;2024-08-19

2. Real-World Data on Subsequent Therapy for First-Line Osimertinib-Induced Pneumonitis: Safety of EGFR-TKI Rechallenge (Osi-risk Study TORG-TG2101);Targeted Oncology;2024-04-13

3. Compromised Outcomes in Stage IV Non–Small-Cell Lung Cancer With Actionable Mutations Initially Treated Without Tyrosine Kinase Inhibitors: A Retrospective Analysis of Real-World Data;JCO Oncology Practice;2024-01

4. Non-small cell lung cancer with bone metastasis and pneumocystis pneumonia in a pregnant woman: a case report and literature review;BMC Infectious Diseases;2023-11-14

5. Investigating Common Mutations in Exon 20 and 21 of EGFR Gene in Lung Cancer Tumor Tissue of NSCLC Type;Gene, Cell and Tissue;2023-11-14

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3